CytomX Therapeutics Inc. (NASDAQ:CTMX) went down by -0.84% during the previous trading session, and it is maintaining the win ahead of Thursday’s trading session. The share price of the Biotechnology giant went up by $8.31 to trade ended Thursday trading at $8.38. This is down from the $8.38 price recorded on Wednesday’s trading session. Thanks to this latest performance, CTMX is closer to the higher price 52-week target of $18.00 and further from the lowest price target of $10.00. Its performance from the start of the year has also been negative, with CTMX down by 0.00% year-to-date.
CytomX Therapeutics Inc. (CTMX) started the day trading at $8.33 and recorded an intraday high of $8.48. It also recorded an intraday low of $8.18 during Thursday’s trading session. CytomX Therapeutics Inc. is a very active stock that recorded a trading volume that is less than -159.8% of the average daily trading volume on Thursday. The stock’s trading volume on Thursday was 265837, which is less than -159.8 of the total average daily trading volume of 690.65K.
CytomX Therapeutics Inc. (NASDAQ:CTMX) 2020 Performance Impressive
The increase in CTMX’s stock price on Thursday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of CTMX currently stands at $15.44, which is higher than the current trading price of the stock by 46.18%. However, CTMX’s current trading price is -130.83% lower than the 52-week low price of $3.60. In terms of trading volume, CytomX Therapeutics Inc. currently experienced healthy participation during the last trading session. 265837 shares of CytomX Therapeutics Inc. were traded on the stock exchange on Thursday, which is less than -159.8% of the 690.65K average trading volume of the stock.
The performance of the stock has been positive over the past year. CTMX’s performance over the past one year has seen it plunge by -32.00%, while the stock has gone up by 2.34% in the last six months. The quarterly performance of CTMX currently stands at -1.07%, and it is up by 3.23% in the last month. The only negative figure was from the weekly performance, which currently reads -2.46%. At the time of writing CTMX’s report, the company has a total market cap of $386.66M, making it one of the largest publicly-traded companies in the world.CytomX Therapeutics Inc. also has over 158 employees all over the world.
CTMX Insider Activities
For CytomX Therapeutics Inc., insiders hold 80.50% of all company shares. The insider transactions over the past six months are up by 0.10%. During that period, insiders bought 37,158 shares in 2 transactions. In that same period, insiders sold 36,000 of their shares in 1 transactions. After these transactions, insiders at CytomX Therapeutics Inc. now hold 1.05M shares, which is over 84.32% of the total company stocks. Institutional investors currently hold a large chunk of the CTMX shares, as they control 2.30% of the company’s total stock.
CTMX Fundamental Analysis
For CytomX Therapeutics Inc., the stock’s diluted earnings per share (EPS) stands at -1.67. In the coming year, analysts expect the EPS to be -2.81. The EPS growth will slow down over the next five years to -0.90% after plunging by -17.70% in the previous five years. In terms of revenue, CytomX Therapeutics Inc.’s quarterly sales (YOY) is growing at 0.05, which is higher than the average annual revenue of -17.70% over the past half a decade.
The Return on Investment (ROI) on CytomX Therapeutics Inc.’s stock currently stands at -216.20%, and it has a net profit margin of -97.80%.
CTMX Analysts Prediction
In June 01, 2020, several analysts reiterated their positions on the CytomX Therapeutics Inc. stock and predicted its performance to their investors. The analysts at Jefferies believe CTMX is still a Hold and set the price target between $16 and $10. The H.C. Wainwright has a Buy rating for CytomX Therapeutics Inc., predicting the stock price to stay between $16 and $12.
Analysts at Wedbush believe that CTMX is Neutral, and they have a price target of between $25 and $8. Guggenheim and Mizuho also believe that CytomX Therapeutics Inc.’s stock is outperforming at the moment. Three analysts, Cantor Fitzgerald, Barclays, and Piper Jaffray, all rate the stock as overweight.
CTMX Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of CTMX currently stands at 0.30%, while the SMA50 is -11.53%. The biggest one is the SMA200, which is currently reading 8.02% ahead of Thursday’s trading session. The Relative Strength Index of this stock is 37.80.